We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

82 hedge funds and large institutions have $284M invested in Avadel Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 24 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

5% more funds holding

Funds holding: 78 → 82 (+4)

0.79% more ownership

Funds ownership: 67.03% → 67.82% (+0.79%)

0% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 24

7% less capital invested

Capital invested by funds: $306M → $284M (-$21.3M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $284K

Holders
82
Holders Change
+4
Holders Change %
+5.13%
% of All Funds
2.04%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.1%
New
11
Increased
24
Reduced
24
Closed
5
Calls
–
Puts
$284K
Net Calls
-$284K
Net Calls Change
-$284K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$5.14M
2
SCM
Stonepine Capital Management
Oregon
+$2.27M
3
Janney Montgomery Scott
Janney Montgomery Scott
Pennsylvania
+$1.91M
4
Boston Partners
Boston Partners
Massachusetts
+$1.7M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.2M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$5.4M
2
Deutsche Bank
Deutsche Bank
Germany
-$4.09M
3
JGC
J. Goldman & Co
New York
-$2.62M
4
William Blair & Company
William Blair & Company
Illinois
-$1.99M
5
FPC
Falcon Point Capital
California
-$1.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
DTL
51
Dynamic Technology Lab
Singapore
$205K +$186K +19,491 New
CLOS
52
Compagnie Lombard Odier SCmA
Switzerland
$199K +$181K +19,000 New
PAM
53
Panagora Asset Management
Massachusetts
$195K +$177K +18,572 New
CSS
54
Cubist Systematic Strategies
Connecticut
$184K +$167K +17,531 New
SEI Investments
55
SEI Investments
Pennsylvania
$183K +$44.7K +4,678 +37%
CCM
56
Condor Capital Management
New Jersey
$176K – – –
CAM
57
Close Asset Management
United Kingdom
$157K – – –
Northern Trust
58
Northern Trust
Illinois
$154K -$3.27K -342 -2%
VF
59
Virtu Financial
New York
$139K +$126K +13,208 New
NCCM
60
Nine Chapters Capital Management
New Jersey
$132K +$120K +12,600 New
US Bancorp
61
US Bancorp
Minnesota
$131K – – –
Susquehanna International Group
62
Susquehanna International Group
Pennsylvania
$117K +$106K +11,122 New
IAMOG
63
Investors Asset Management of Georgia
Georgia
$116K – – –
Citigroup
64
Citigroup
New York
$102K -$12.7K -1,325 -12%
BWP
65
Baldwin Wealth Partners
Massachusetts
$98K – – –
IA
66
IFP Advisors
Florida
$90K – – –
PCM
67
Prelude Capital Management
New York
$72K +$27.7K +2,900 +73%
Royal Bank of Canada
68
Royal Bank of Canada
Ontario, Canada
$64K – – –
Barclays
69
Barclays
United Kingdom
$43K +$9.55K +1,000 +33%
Bank of Montreal
70
Bank of Montreal
Ontario, Canada
$42K – – –
TRCT
71
Tower Research Capital (TRC)
New York
$33K -$13.4K -1,407 -31%
Wells Fargo
72
Wells Fargo
California
$16K +$4.88K +511 +51%
AG
73
Advisor Group
Arizona
$15K +$439 +46 +3%
Envestnet Asset Management
74
Envestnet Asset Management
Illinois
$5K -$248 -26 -5%
WC
75
Whitnell & Co
Illinois
$5K – – –
1 2
3
4

AVDL Hedge Fund Activity: Q3 2017 in Review

82 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2017, worth a combined $284M — down 7% from $306M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new AVDL positions and 5 closed out — a net gain of 6 holders — while 24 added to existing stakes and 24 trimmed.

The largest buyer was Armistice Capital, adding an estimated $5.14M. The largest seller was Broadfin Capital, cutting an estimated $5.4M.

  • 82 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2017, up from 78 in Q2 2017.
  • Funds reported $284M of Avadel Pharmaceuticals stock for Q3 2017, down 7% quarter-over-quarter.
  • 11 funds opened new Avadel Pharmaceuticals positions in Q3 2017 and 5 closed out, a net change of +6 holders.
  • The largest Avadel Pharmaceuticals buyer in Q3 2017 was Armistice Capital, an estimated $5.14M added.
  • The largest Avadel Pharmaceuticals seller in Q3 2017 was Broadfin Capital, an estimated $5.4M sold.

Based on aggregated 13F filings for Q3 2017.